We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Microfluidic Blood-Cleansing Device Battles Sepsis

By HospiMedica International staff writers
Posted on 05 Oct 2014
A dialysis-like therapeutic device inspired by the human spleen that filters bacteria, fungi, and toxins could radically transform the way doctors treat sepsis.

The biospleen device, developed by researchers at Harvard University (Boston, MA, USA), is a microfluidic filter that consists of two adjacent hollow channels connected to each other by a series of slits: one channel contains flowing blood, and the other contains a saline solution. More...
The key to the device are tiny nanometer-sized magnetic beads coated with a genetically engineered hybrid version of a natural immune system protein called opsonin-mannose-binding lectin (MBL).

The researchers attached the hybrid proteins to magnetic beads (128 nanometers in diameter) that could be added to blood of an infected patient to bind to the pathogens and toxins, without having to first identify the type of infectious agent. A magnet then pulls the pathogen-coated magnetic beads through the channels to cleanse the blood flowing through the device, which is returned to the patient. The researchers decided to first test the system in vitro, using human blood spiked with pathogens.

They found that the device efficiently removed multiple Gram-negative bacteria, Gram-positive bacteria, fungi, and endotoxins from whole human blood flowing through a single biospleen unit at up to 1.25 liters/hour; in principal, many devices could be linked together to cleanse human blood at dialysis-like rates. They also tested the device using rats infected with E. coli, S. aureus, and toxins. Similar to the tests on human blood, and after just five hours of filtering, about 90% of the bacteria and toxin were removed from the rats' bloodstream. The study describing the biospleen device was published on September 14, 2104, in Nature Medicine.

“Sepsis is a major medical threat, which is increasing because of antibiotic resistance. We're excited by the biospleen because it potentially provides a way to treat patients quickly without having to wait days to identify the source of infection, and it works equally well with antibiotic-resistant organisms,” said senior author Prof. Donald Ingber, MD, PhD, founding director of the Harvard Wyss Institute for Biologically Inspired Engineering. “We hope to move this towards human testing to advancing to large animal studies as quickly as possible.”

Sepsis, which causes millions of deaths globally each year, is characterized by an inflammatory state resulting from the immune system's response to a serious infection triggered by bacteria, fungi, viruses, and parasites in the blood, urinary tract, lungs, skin, or other tissues. Common symptoms of sepsis include those related to a specific infection, but are usually accompanied by high fevers, hot, flushed skin, elevated heart rate, hyperventilation, altered mental status, swelling, and low blood pressure.

Related Links:

Harvard University
Wyss Institute for Biologically Inspired Engineering



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Wound Irrigation Solution
Prontosan®
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: A UTSW clinical trial studied a treatment strategy for kidney cancer with inferior vena cava tumor thrombus (IVC-TT) that used targeted radiation on the tumor thrombus followed by surgery to remove the kidney. (Photo courtesy of UT Southwestern)

Targeted Radiotherapy Before Surgery Improves Control of Kidney Cancer Thrombus

Inferior vena cava tumor thrombus occurs when kidney cancer extends into the body’s largest vein, potentially obstructing blood flow, progressing toward the heart, and making surgery more complex.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.